"This is an entirely new approach to study a huge public health issue," Delp said. "It's a completely new tool that is now available to neuroscientists everywhere."
The mice are modified with gene therapy to have pain-sensing nerves that can be controlled by light. One color of light makes the mice more sensitive to pain. Another reduces pain. The light was shone on the paws of mice through the Plexiglas bottom of the cage.
The findings of the research were published online Feb. 16 in Nature Biotechnology. Delp was the senior author. The lead authors were graduate students Shrivats Iyer and Kate Montgomery. The researchers said the study opens the door to future experiments on the nature of pain, touch and other sensations that now are poorly understood.
"The fact that we can give a mouse an injection and two weeks later shine a light on its paw to change the way it senses pain is very powerful," Iyer said.
For example, increasing or decreasing the sensation of pain in these mice could help scientists understand why pain seems to continue in people after an injury has healed. Does persistent pain change those nerves in some way? And if so, how can they be changed back to a state in which, absent an injury, they stop sending pain messages to the brain?
Leaders at the National Institutes of Health agree that the work could have important implications for treating pain. "This powerful approach shows great potential for helping the millions who suffer pain from nerve damage," said Linda Porter, the pain policy adviser at the National Institute of Neurological Disorders and Stroke and a leader of the NIH's Pain Consortium.
The researchers took advantage of a technique called optogenetics, which involves light-sensitive proteins called opsins that are inserted into the nerves. Optogenetics was developed by Delp's colleague Karl Deisseroth, MD, PhD, a co-author of the paper. He has used the technique as a way of activating precise regions of the rodent brain to better understand how the brain functions. Deisseroth is a professor of bioengineering and of psychiatry and behavioral sciences, as well as a Howard Hughes Medical Institute investigator.
Delp, who has an interest in muscles and movement, saw the potential for using optogenetics not just for studying the brain but also for studying the many nerves outside the brain. These are the nerves that control movement, pain, touch and other sensations throughout our body and that are involved in diseases like amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.
A few years ago, Stanford's Bio-X program, which encourages interdisciplinary projects like this one, supported Delp and Deisseroth in their efforts to use optogenetics to control the nerves in mice that excite muscles. In the process of doing that work, Delp said, a student of his at the time, Michael Llewellyn, would occasionally find that he would place the opsins into nerves that signal pain rather than the ones that control muscle.
That accident sparked a new line of research. "We thought, wow, we're getting pain neurons - that could be really important," Delp said. He suggested that Montgomery and Iyer focus on those pain nerves that had been a byproduct of the muscle work.
A key component of the work was a new approach to quickly incorporate opsins into the nerves of mice. The team started with a virus that had been engineered to contain the DNA that produces the opsin. Then they injected those modified viruses directly into mouse nerves. Weeks later, only the nerves that control pain had incorporated the opsin proteins and would fire, or be less likely to fire, in response to different colors of light.
The speed of the viral approach makes it very flexible, both for this work and for future studies, the study's authors said. Researchers are developing newer forms of opsins with different properties. (Current opsins respond to light on the bluish end of spectrum, which doesn't penetrate very deeply into body tissues) "Because we used a viral approach, we could, in the future, quickly turn around and use newer opsins," said Montgomery, a Stanford Bio-X fellow.
This entire project, which spans bioengineering, neuroscience and psychiatry, could never have happened without the environment at Stanford that supports collaboration across departments, Delp said. The pain portion of the research came out of support from NeuroVentures, which was a project incubated within Bio-X to support the intersection of neuroscience and engineering or other disciplines. That project was so successful it has spun off into the Stanford Neurosciences Institute, of which Delp is now a deputy director.
Delp said there are many challenges to meet before new drugs and medical techniques that result from these experiments could become available to people, but that he always has that as a goal.
"Developing a new therapy from the ground up would be incredibly rewarding," he said. "Most people don't get to do that in their careers."
Other Stanford co-authors of the study were postdoctoral scholars Chris Towne, PhD, and Soo Yeun Lee, PhD; and research assistant Charu Ramakrishnan.
The study was supported by the NIH and Bio-X, as well as by fellowships from the Stanford Office of Technology Licensing, the Howard Hughes Medical Institute, the Office of the Vice Provost for Graduate Education and the Swiss National Science Foundation.
- See more at: http://med.stanford.edu/ism/2014/march/pain-0310.html#sthash.WvBhbBz1.dpuf
For advertising and promotion on HealthNewsDigest.com, call Mike McCurdy: 877-634-9180 or [email protected] We have over 7,000 journalists as subscribers.